Abstract:PurposeThe goal of the study is to conclude local control rate, overall survival of brachytherapy using I-125 radioactive seeds for treating malignant sublingual gland tumors.Materials and MethodsFifty-eight patients of malignant tumor derived from sublingual gland, either primary or recurrent, including twenty-seven male and thirty-one female, were collected in the study. The median age was 53.5, ranging from 24 to 78. There were 44 adenoid cystic carcinoma, 7 mucoepidermoid carcinoma, 4 adenoid carcinoma, 2 malignant pleomorphic adenoma and 1 acinic cell carcinoma. The stage for patients, 60.5% was for early state (stage I and II), 39.5% was for late stage (stage III and IV). Forty-three patients were treated by surgical resection combined adjuvant brachytherapy and fifteen patients were treated by brachytherapy alone. Twenty-eight were local tumor resection and fifteen were composite procedures, including six segmental mandibulectomy, five marginal jaw resection and four submandibular gland resection. Selective neck resection was performed in ten patients. Brachytherapy were designed by treatment planning system. Patients were implanted a mean amount of 51 I-125 radioactive seeds, ranging from 8∼147 seeds. The total seeds activity was 24.5mCi (1361.6MBq) on average. The prescription dose ranged from 60∼140Gy. Each patient received quality verification and was followed up. Kaplan-Meier analysis were performed.ResultsFifty-eight patients were followed up for 8∼167 months, median time was 49 months. There were twelve local failures and six of which caused death, ten distant metastasis and five of which caused death. Three patients suffered tongue squamous cell cancer 2-6 years after brachytherapy, sebsequently performed tumor resection and free flap reconstruction, one of whom eventually died of tongue cancer after several times surgery. The 1-year, 3-year and 5-year local control rate was 94.8%, 87.5% and 78.7% respectively. Kaplan-Meier analysis was used for overall survival (OS) and disease free survival (DFS). OS for 3-year, 5-year and 10-year was 85.7%, 80% and 73.4% respectively. DFS for 3-year, 5-year and 10-year was 83.5%, 79.5% and 71.6% respectively. Univariate analysis showed that stage, metastasis, and surgery had significant impact on OS (p=0.012, p<0.001, p<0.001). Of late stage patient, surgery combined adjuvant brachytherapy increased OS and DFS significantly than brachytherapy alone (p<0.001), whereas of early stage patients, surgery performed or not didn't show significant impact on OS (p=0.315). Gender, recurrent tumor and pathology showed no impact on OS. Multivariate analysis demonstrated that distant metastasis and treatment style were predictors for OS (p=0.011, p=0.010) and DFS (p=0.004, p=0.031). One patient suffered from osteomyelitis, two patients suffered from post-brachytherapy infection and healed eventually. No severe xerostomia and limitation of mouth opening was observed.Conclusions PurposeThe goal of the study is to conclude local control rate, overall survival of brachytherapy using I-125 radioactive seeds for treating malignant sublingual gland tumors. The goal of the study is to conclude local control rate, overall survival of brachytherapy using I-125 radioactive seeds for treating malignant sublingual gland tumors. Materials and MethodsFifty-eight patients of malignant tumor derived from sublingual gland, either primary or recurrent, including twenty-seven male and thirty-one female, were collected in the study. The median age was 53.5, ranging from 24 to 78. There were 44 adenoid cystic carcinoma, 7 mucoepidermoid carcinoma, 4 adenoid carcinoma, 2 malignant pleomorphic adenoma and 1 acinic cell carcinoma. The stage for patients, 60.5% was for early state (stage I and II), 39.5% was for late stage (stage III and IV). Forty-three patients were treated by surgical resection combined adjuvant brachytherapy and fifteen patients were treated by brachytherapy alone. Twenty-eight were local tumor resection and fifteen were composite procedures, including six segmental mandibulectomy, five marginal jaw resection and four submandibular gland resection. Selective neck resection was performed in ten patients. Brachytherapy were designed by treatment planning system. Patients were implanted a mean amount of 51 I-125 radioactive seeds, ranging from 8∼147 seeds. The total seeds activity was 24.5mCi (1361.6MBq) on average. The prescription dose ranged from 60∼140Gy. Each patient received quality verification and was followed up. Kaplan-Meier analysis were performed. Fifty-eight patients of malignant tumor derived from sublingual gland, either primary or recurrent, including twenty-seven male and thirty-one female, were collected in the study. The median age was 53.5, ranging from 24 to 78. There were 44 adenoid cystic carcinoma, 7 mucoepidermoid carcinoma, 4 adenoid carcinoma, 2 malignant pleomorphic adenoma and 1 acinic cell carcinoma. The stage for patients, 60.5% was for early state (stage I and II), 39.5% was for late stage (stage III and IV). Forty-three patients were treated by surgical resection combined adjuvant brachytherapy and fifteen patients were treated by brachytherapy alone. Twenty-eight were local tumor resection and fifteen were composite procedures, including six segmental mandibulectomy, five marginal jaw resection and four submandibular gland resection. Selective neck resection was performed in ten patients. Brachytherapy were designed by treatment planning system. Patients were implanted a mean amount of 51 I-125 radioactive seeds, ranging from 8∼147 seeds. The total seeds activity was 24.5mCi (1361.6MBq) on average. The prescription dose ranged from 60∼140Gy. Each patient received quality verification and was followed up. Kaplan-Meier analysis were performed. ResultsFifty-eight patients were followed up for 8∼167 months, median time was 49 months. There were twelve local failures and six of which caused death, ten distant metastasis and five of which caused death. Three patients suffered tongue squamous cell cancer 2-6 years after brachytherapy, sebsequently performed tumor resection and free flap reconstruction, one of whom eventually died of tongue cancer after several times surgery. The 1-year, 3-year and 5-year local control rate was 94.8%, 87.5% and 78.7% respectively. Kaplan-Meier analysis was used for overall survival (OS) and disease free survival (DFS). OS for 3-year, 5-year and 10-year was 85.7%, 80% and 73.4% respectively. DFS for 3-year, 5-year and 10-year was 83.5%, 79.5% and 71.6% respectively. Univariate analysis showed that stage, metastasis, and surgery had significant impact on OS (p=0.012, p<0.001, p<0.001). Of late stage patient, surgery combined adjuvant brachytherapy increased OS and DFS significantly than brachytherapy alone (p<0.001), whereas of early stage patients, surgery performed or not didn't show significant impact on OS (p=0.315). Gender, recurrent tumor and pathology showed no impact on OS. Multivariate analysis demonstrated that distant metastasis and treatment style were predictors for OS (p=0.011, p=0.010) and DFS (p=0.004, p=0.031). One patient suffered from osteomyelitis, two patients suffered from post-brachytherapy infection and healed eventually. No severe xerostomia and limitation of mouth opening was observed. Fifty-eight patients were followed up for 8∼167 months, median time was 49 months. There were twelve local failures and six of which caused death, ten distant metastasis and five of which caused death. Three patients suffered tongue squamous cell cancer 2-6 years after brachytherapy, sebsequently performed tumor resection and free flap reconstruction, one of whom eventually died of tongue cancer after several times surgery. The 1-year, 3-year and 5-year local control rate was 94.8%, 87.5% and 78.7% respectively. Kaplan-Meier analysis was used for overall survival (OS) and disease free survival (DFS). OS for 3-year, 5-year and 10-year was 85.7%, 80% and 73.4% respectively. DFS for 3-year, 5-year and 10-year was 83.5%, 79.5% and 71.6% respectively. Univariate analysis showed that stage, metastasis, and surgery had significant impact on OS (p=0.012, p<0.001, p<0.001). Of late stage patient, surgery combined adjuvant brachytherapy increased OS and DFS significantly than brachytherapy alone (p<0.001), whereas of early stage patients, surgery performed or not didn't show significant impact on OS (p=0.315). Gender, recurrent tumor and pathology showed no impact on OS. Multivariate analysis demonstrated that distant metastasis and treatment style were predictors for OS (p=0.011, p=0.010) and DFS (p=0.004, p=0.031). One patient suffered from osteomyelitis, two patients suffered from post-brachytherapy infection and healed eventually. No severe xerostomia and limitation of mouth opening was observed. Conclusions

Abstract:Purpose/Objective(s)The role of adjuvant chemoradiation therapy (CRT) in locally advanced gastric cancer (LAGC) after D2 dissection is still controversial. The ARTIST trial failed to achieve disease-free survival (DFS) improvement from CRT compared to chemotherapy (CT) alone, but in subgroup analysis they discovered positive lymph node as a predictive factor for selective additional radiation; however, the majority of the patients enrolled in the study were relatively early-stage, limiting its application in the Chinese population where most LAGC patients were stage III. This retrospective study compared adjuvant CRT versus adjuvant chemotherapy (CT) after D2 dissection in patients with LAGC, and provided directions for patient selection.Materials/MethodsFour hundred twelve patients with LAGC (stage IB-IIIC) who underwent radical surgery (D2, R0) were retrospectively investigated. Patients were divided into two balanced groups based on clinical and pathological characteristics. Half of the patients (206) received adjuvant CRT, and the other half received adjuvant CT alone. Chemotherapies were fluorouracil-based regimens, and radiation was given 45 Gy (45-50.4 Gy) using 3D conformal or intensive modulation radiation therapy (IMRT) techniques. Concurrent chemotherapy was 5-fluorouracil 225 mg/m2/d weekly intravenously or capecitabine 625mg/m2/d BID d1-5 weekly.ResultsAfter a median follow-up of 39 (range, 3-92) months, of the 412 patients, 200 deaths were observed (93 in CRT group and 107 in CT group), and 212 experienced recurrence (92 in CRT group and 120 in CT group). Most of the patients (81.1%) were in stage III. The estimated 3-year DFS and overall survival (OS) in CRT and CT group was 49.5% versus 46.1% (P = .04), and 57.2% versus 52.9% (P = .18), respectively. The CT group had obviously increased risk of local regional recurrence compared to the CRT group (15.6% vs 8.7%, P = .01, respectively), while metastasis to peritoneal and distant organs were similar between the two groups (22.8% vs 20.3%, P = .39; 27.7% vs 22.3% P = .07, respectively). In subgroup analysis, male, over 60 years old, N1-2 were predictive factors for better survival from adjuvant CRT (HR = 1.48, 1.80, 1.72, respectively), while N3 patients failed to benefit from additional radiation. Multivariate analysis identified positive lymph nodes and receiving CRT as independent prognostic factors of DFS (HR = 0.40, P = .00; HR = 1.38, P = .02, respectively).ConclusionAdjuvant CRT could improve 3-year DFS and local control in patients of LAGC after D2 dissection. Male, over 60 years old, N1-2 were predictive factors for selective adjuvant CRT. Further studies should be focused on integrating clinical and molecular factors to identify targeted patients for selective adjuvant CRT. Purpose/Objective(s)The role of adjuvant chemoradiation therapy (CRT) in locally advanced gastric cancer (LAGC) after D2 dissection is still controversial. The ARTIST trial failed to achieve disease-free survival (DFS) improvement from CRT compared to chemotherapy (CT) alone, but in subgroup analysis they discovered positive lymph node as a predictive factor for selective additional radiation; however, the majority of the patients enrolled in the study were relatively early-stage, limiting its application in the Chinese population where most LAGC patients were stage III. This retrospective study compared adjuvant CRT versus adjuvant chemotherapy (CT) after D2 dissection in patients with LAGC, and provided directions for patient selection. The role of adjuvant chemoradiation therapy (CRT) in locally advanced gastric cancer (LAGC) after D2 dissection is still controversial. The ARTIST trial failed to achieve disease-free survival (DFS) improvement from CRT compared to chemotherapy (CT) alone, but in subgroup analysis they discovered positive lymph node as a predictive factor for selective additional radiation; however, the majority of the patients enrolled in the study were relatively early-stage, limiting its application in the Chinese population where most LAGC patients were stage III. This retrospective study compared adjuvant CRT versus adjuvant chemotherapy (CT) after D2 dissection in patients with LAGC, and provided directions for patient selection. Materials/MethodsFour hundred twelve patients with LAGC (stage IB-IIIC) who underwent radical surgery (D2, R0) were retrospectively investigated. Patients were divided into two balanced groups based on clinical and pathological characteristics. Half of the patients (206) received adjuvant CRT, and the other half received adjuvant CT alone. Chemotherapies were fluorouracil-based regimens, and radiation was given 45 Gy (45-50.4 Gy) using 3D conformal or intensive modulation radiation therapy (IMRT) techniques. Concurrent chemotherapy was 5-fluorouracil 225 mg/m2/d weekly intravenously or capecitabine 625mg/m2/d BID d1-5 weekly. Four hundred twelve patients with LAGC (stage IB-IIIC) who underwent radical surgery (D2, R0) were retrospectively investigated. Patients were divided into two balanced groups based on clinical and pathological characteristics. Half of the patients (206) received adjuvant CRT, and the other half received adjuvant CT alone. Chemotherapies were fluorouracil-based regimens, and radiation was given 45 Gy (45-50.4 Gy) using 3D conformal or intensive modulation radiation therapy (IMRT) techniques. Concurrent chemotherapy was 5-fluorouracil 225 mg/m2/d weekly intravenously or capecitabine 625mg/m2/d BID d1-5 weekly. ResultsAfter a median follow-up of 39 (range, 3-92) months, of the 412 patients, 200 deaths were observed (93 in CRT group and 107 in CT group), and 212 experienced recurrence (92 in CRT group and 120 in CT group). Most of the patients (81.1%) were in stage III. The estimated 3-year DFS and overall survival (OS) in CRT and CT group was 49.5% versus 46.1% (P = .04), and 57.2% versus 52.9% (P = .18), respectively. The CT group had obviously increased risk of local regional recurrence compared to the CRT group (15.6% vs 8.7%, P = .01, respectively), while metastasis to peritoneal and distant organs were similar between the two groups (22.8% vs 20.3%, P = .39; 27.7% vs 22.3% P = .07, respectively). In subgroup analysis, male, over 60 years old, N1-2 were predictive factors for better survival from adjuvant CRT (HR = 1.48, 1.80, 1.72, respectively), while N3 patients failed to benefit from additional radiation. Multivariate analysis identified positive lymph nodes and receiving CRT as independent prognostic factors of DFS (HR = 0.40, P = .00; HR = 1.38, P = .02, respectively). After a median follow-up of 39 (range, 3-92) months, of the 412 patients, 200 deaths were observed (93 in CRT group and 107 in CT group), and 212 experienced recurrence (92 in CRT group and 120 in CT group). Most of the patients (81.1%) were in stage III. The estimated 3-year DFS and overall survival (OS) in CRT and CT group was 49.5% versus 46.1% (P = .04), and 57.2% versus 52.9% (P = .18), respectively. The CT group had obviously increased risk of local regional recurrence compared to the CRT group (15.6% vs 8.7%, P = .01, respectively), while metastasis to peritoneal and distant organs were similar between the two groups (22.8% vs 20.3%, P = .39; 27.7% vs 22.3% P = .07, respectively). In subgroup analysis, male, over 60 years old, N1-2 were predictive factors for better survival from adjuvant CRT (HR = 1.48, 1.80, 1.72, respectively), while N3 patients failed to benefit from additional radiation. Multivariate analysis identified positive lymph nodes and receiving CRT as independent prognostic factors of DFS (HR = 0.40, P = .00; HR = 1.38, P = .02, respectively). ConclusionAdjuvant CRT could improve 3-year DFS and local control in patients of LAGC after D2 dissection. Male, over 60 years old, N1-2 were predictive factors for selective adjuvant CRT. Further studies should be focused on integrating clinical and molecular factors to identify targeted patients for selective adjuvant CRT. Adjuvant CRT could improve 3-year DFS and local control in patients of LAGC after D2 dissection. Male, over 60 years old, N1-2 were predictive factors for selective adjuvant CRT. Further studies should be focused on integrating clinical and molecular factors to identify targeted patients for selective adjuvant CRT.

I-125 Seeds Permanent Interstitial Brachytherapy to Treat Malignant Sublingual Gland Tumors: A Clinical Retrospective Study

Oncological Outcome of Patients with Salivary Gland Cancer Treated with Surgery and Postoperative Intensity-Modulated Radiotherapy: a Retrospective Study

A SEER Database Analysis of Urethral Cancer Management

(125)I Seed Interstitial Brachytherapy for Recurrent Pleomorphic Adenoma

Brachytherapy for Recurrent Malignant Tumours of the Parotid Gland.

Selective Nodal Irradiation by Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma Aiming to Reduce Dysphagia and Xerostomia

The Efficacy of Iodine-125 Interstitial Brachytherapy for the Treatment of Locally Advanced Adenoid Cystic Carcinoma of the Base of Tongue: a Non-Surgical Approach.

Comparison of Outcomes Using Radiotherapy or Brachytherapy after Resection of Primary Adenoid Cystic Carcinoma in Oral and Maxillofacial Regions.

Clinicopathologic Analysis Of Oral Squamous Cell Carcinoma After I-125 Interstitial Brachytherapy

Who Will Benefit from Adjuvant Chemoradiation Therapy in Patients with Locally Advanced Gastric Cancer Following D2 Dissection: Do N3 Patients Need Additional Radiation?

Definitive 125I Brachytherapy of Locally Advanced Adenoid Cystic Carcinoma Involving the Skull Base with Satisfying Efficacy and Safety.

The Clinical Results and Physical Dosimetry Study of 3D-Printing Template Assisted with CT-Guidance for 125I Seed Brachytherapy in Recurrent or Metastatic Gynecologic Carcinoma

Three-Dimensional-Printed Template-Guided Radioactive Seed Brachytherapy Via a Submental Approach for Recurrent Base of Tongue and Floor of Mouth Cancer

Application of 125I interstitial brachytherapy in the treatment of local advanced parotid adenoid cystic carcinoma

Radioactivity Seeds Interstitial Brachtherapy Treating Malignant Salivary Gland Tumors

Preliminary Results of (125)I Interstitial Brachytherapy for Locally Recurrent Parotid Gland Cancer in Previously Irradiated Patients.

Comparative Effectiveness of Brachytherapy As Local Treatment Versus No Local Treatment for Metastatic Prostate Cancer: A SEER Analysis

Abstract 4853: Impact of different therapeutic strategies on survival in laryngeal squamous cell carcinoma (LSCC)

Distant metastases of malignant salivary gland carcinoma after treated by 125Ⅰ internal brachy therapy alone

Postoperative Iodine-125 Interstitial Brachytherapy for the Early Stages of Minor Salivary Gland Carcinomas of the Lip and Buccal Mucosa with Positive or Close Margins

Iodine-125 Brachytherapy Alone for Advanced Primary Parotid Gland Carcinoma.